The FLAURA2 study

Prof dr Pasi Jänne, medical oncologist at the  Dana Farber Cancer Institute, Boston, MA, USA presented the outcomes of the FLAURA study during the presidential symposium at WCLC. FLAURA2 is a global, phase III, open-label, randomized study evaluating the efficacy and safety of first-line osimertinib plus chemotherapy versus osimertinib monotherapy for EGFRm advanced non-small cell lung cancer (NSCLC). The combination of osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful benefit over osimertinib monotherapy, with a manageable safety/tolerability profile. Prof. Jänne concluded that these data support osimertinib plus chemotherapy as a new first-line treatment option in advanced EGFRm NSCLC.

With the educational support of: